drugset / Trial / NCT02198443
Comparison of Two Combinations in Antiretroviral Post-Exposure Prophylaxis for HIV-1: Tenofovir/Emtricitabine (Truvada ®) + Lopinavir/Ritonavir (Kaletra ®) vs Tenofovir/Emtricitabine/Cobicistat/Elvitegravir (Stribild ®). Prospective, Randomized, Open.
RandomizedParallel-groupOpen-labelPrevention
Summary
The main objective of this study is to compare the tolerability and adherence to a new drug regimen of post-exposure prophylaxis (PEP) for HIV,
Timeline
- Start
- 2015-06-06
- Primary completion
- 2016-07-15
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cobicistat | Small molecule | 150 mg | — |
| Comparator | Lopinavir | Other / unclassified | 200 mg | — |
| Comparator | Ritonavir | Other / unclassified | 50 mg | — |
| Comparator | Tenofovir | Small molecule | 245 mg | — |
| Subject | Tenofovir disoproxil fumarate | Small molecule | 245 mg | — |
| Subject | elvitegravir | Small molecule | 150 mg | — |
| Subject | emtricitabine | Other / unclassified | 200 mg | — |